Robert Uger - May 7, 2021 Form 4 Insider Report for Trillium Therapeutics Inc. (TRIL)

Role: Chief Scientific Officer
Signature: /s/ James Parsons, Attorney-in-Fact
Stock symbol: TRIL
Transactions as of: May 7, 2021
Transactions value $: -$32,767
Form type: 4
Date filed: 5/11/2021, 04:24 PM
Next filing: Jun 9, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TRIL	Common Shares	Options Exercise	$1.14K	+3.65K		$0.31^*	3.65K	May 7, 2021	Direct	F1, F2
transaction	TRIL	Common Shares	Sale	-$33.9K	-3.65K	-100%	$9.30^*	0	May 7, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TRIL	Stock Option (Right to Buy)	Options Exercise	$0	-3.65K	-3.23%	$0.00	109K	May 7, 2021	Common Shares	3.65K	$0.31	Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2	The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.8237 USD.
F3	25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months.